News
CAI
25.57
+1.35%
0.34
BTSG vs. CAI: Which Stock Should Value Investors Buy Now?
NASDAQ · 19h ago
Weekly Report: what happened at CAI last week (1102-1106)?
Weekly Report · 1d ago
Caris Life Sciences Is Maintained at Buy by Citigroup
Dow Jones · 3d ago
Caris Life Sciences Price Target Raised to $36.00/Share From $28.00 by Citigroup
Dow Jones · 3d ago
Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36
Benzinga · 3d ago
Analysts Offer Insights on NA Companies: Canadian National Railway (CNI), Caris Life Sciences, Inc. (CAI) and Figma, Inc. Class A (FIG)
TipRanks · 3d ago
Caris Life Sciences price target raised to $36 from $28 at Citi
TipRanks · 3d ago
Analysts Conflicted on These NA Names: Lyntris Inc (LYNX), Ardent Health Partners, Inc. (ARDT) and Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Caris Life Sciences: Strong Q3 Execution and Raised 2026 Outlook Tempered by Profitability Pressure; Hold, $30 Price Target Unchanged
TipRanks · 4d ago
Caris Life Sciences Is Maintained at Buy by TD Cowen
Dow Jones · 4d ago
Caris Life Sciences Price Target Raised to $38.00/Share From $36.00 by TD Cowen
Dow Jones · 4d ago
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Benzinga · 4d ago
VIX Spikes 39% as AI Tech Rout Wipes Out $2.2 Trillion: Stock Market Today
Benzinga · 4d ago
Caris Life Sciences Down Over 20%, on Track for Record Percent Decrease -- Data Talk
Dow Jones · 4d ago
Caris Life (CAI) Q3 2026 Earnings Call Transcript
The Motley Fool · 4d ago
Piper Sandler Remains a Hold on Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Morning Movers: AppLovin surges following third quarter results
TipRanks · 4d ago
Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 4d ago
Analysts’ Opinions Are Mixed on These NA Stocks: Caris Life Sciences, Inc. (CAI) and Corpay Inc (CPAY)
TipRanks · 4d ago
Goldman Sachs Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
More
Webull provides a variety of real-time CAI stock news. You can receive the latest news about Caris Life Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.